Abstract
There has been a constant requirement from the clinic to develop biomedical titanium (Ti) implants with high osteogenic ability. In this study, we clarified a novel mechanism of how MAO (microarc oxidation) coating of Ti implants facilitates osteogenic differentiation of human bone marrow mesenchymal stem cells (hB-MSCs) by activating ERK1/2-miR-1827-Osterix signaling pathway in vitro. MAO surface of titanium implant was more favorable to promote osteogenic differentiation than SLA and AOS coating. Besides, titanium implants regulated hB-MSCs osteogenesis through the p38 MAPK pathway and ERK1/2 might be the most efficient target. Furthermore, MAO coating induced osteogenic differentiation though ERK1/2-miR-1827 pathway. Finally, we verified miR-1827 regulated osteogenic differentiation partially through Osterix. Our study reveals novel insights that MAO surface of titanium implant is a prior choice for biomedical trial and for its use in periprosthetic osteolysis (PIO) treatment in an evidence-based rationale.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
